Lifeward Ltd. (LFWD): debt financing — Lifeward Q3 revenue $6.2M (+1% YoY); net loss $0.20/shr; secures $3M loan from Oramed

Lifeward Ltd.

2025-Q3 EPS reported -$1.16 revenue$16,953,000

Revenue $6.2M (+1% YoY); traditional products up 24% to $3.1M; AlterG down 15% to $3.1M.
GAAP net loss $3.2M ($0.20/shr); non-GAAP net loss $3.0M ($0.19/shr) vs $4.0M ($0.45/shr) YoY.
Cash used in ops $3.8M (down from $4.5M YoY); unrestricted cash $2.0M at quarter end.
Entered $3.0M secured loan from Oramed at 15%, convertible at $0.45/shr, matures May 2026.
Reaffirmed FY2025 guidance: revenue $24-26M; non-GAAP net loss $12-14M.

item 1.01 item 2.02 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Lifeward Ltd. incurred loan of $3.0 million with Oramed Ltd. at 15% per annum maturing May 14, 2026.

Instrument: loan
Principal: $3.0 million
Counterparty: Oramed Ltd.
Rate: 15% per annum
Maturity: May 14, 2026
Event: incurrence

Exact text from the filing

On November 14, 2025, Lifeward Ltd. (the “Company,” “we” or “us”) entered into a Secured Promissory Note (the “Secured Promissory Note”) with Oramed Ltd. (“Oramed”) pursuant to which, we issued to Oramed a secured promissory note in the principal amount of $3.0 million.

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-25-003837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.